Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

75.69
-2.9200-3.71%
Volume:354.73K
Turnover:27.26M
Market Cap:3.32B
PE:-69.93
High:79.10
Open:78.45
Low:75.47
Close:78.61
52wk High:91.53
52wk Low:53.89
Shares:43.88M
Float Shares:35.64M
Volume Ratio:0.54
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0824
EPS(LYR):-1.5900
ROE:-13.68%
ROA:-5.48%
PB:9.58
PE(LYR):-47.60

Loading ...

Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus

Simply Wall St.
·
Aug 09

Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating

MT Newswires Live
·
Aug 07

Tarsus Pharmaceuticals Balances XDEMVY Surge With Retina Bet

TIPRANKS
·
Aug 07

Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate

Benzinga Earnings
·
Aug 07

Verrica Pharma Reports Wider-than-Expected Q2 Adj Loss Per Share

Reuters
·
Aug 07

Tarsus Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Tarsus Pharmaceuticals announces $125M private placement

TIPRANKS
·
Aug 06

Tarsus Pharmaceuticals Q2 Sales Beat Estimates, Lifts 2026 Xdemvy Sales Outlook

Reuters
·
Aug 06

Tarsus to Buy Alkeus in Deal Worth About $450 Million Upfront

Reuters
·
Aug 06

Tarsus Prices USD 125 Million PIPE at USD 56 Per Share

Reuters
·
Aug 06

Tarsus Q2 FY26 Net Loss Narrows 8.77% to $18.55 Million; Net Product Sales Rise More than 69% to $173.91 Million

Reuters
·
Aug 06

Tarsus Pharmaceuticals Q2 EPS USD -0.43

THOMSON REUTERS
·
Aug 06

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

THOMSON REUTERS
·
Aug 06

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

THOMSON REUTERS
·
Aug 06

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

THOMSON REUTERS
·
Aug 06

Tarsus Pharmaceuticals, - up to $350 Mln in Milestone Payments upon Regulatory Approval and First Sale

THOMSON REUTERS
·
Aug 06

Tarsus Pharmaceuticals, - Deal Includes $450 Mln Upfront, $270 Mln Cash, $180 Mln in Tarsus Stock

THOMSON REUTERS
·
Aug 06

Tarsus Pharmaceuticals to Report Q2 2026 Results, Host Webcast

Reuters
·
Aug 06

Tarsus Pharmaceuticals is Maintained at Outperform by Mizuho

Dow Jones
·
Aug 01

Mizuho Trims Price Target on Tarsus Pharmaceuticals to $98 From $100, Keeps Outperform Rating

MT Newswires Live
·
Jul 31